Helsinn Investment Fund

Helsinn Investment Fund is a venture capital firm focused on early-stage investments in areas of high unmet patient need. Backed by the Helsinn Group, the fund aims to help companies with innovative technologies transform new ideas into commercial solutions that can impact the health-related quality of life of patients. Drawing on Helsinn's over 40 years of expertise in research and development and commercialization of therapeutic candidates in cancer care, pain and inflammation, and gastroenterology, the fund selects companies with technologies in areas including cancer therapeutics and diagnostics, cancer supportive care, metabolic and gastrointestinal disorders, and dermatology conditions.

The fund's investment strategy involves providing scientific and clinical strategy guidance, operational and board support alongside ongoing investment. It focuses on companies with strong science and technology that have achieved at least preclinical proof of concept, and ideally with clinical data. Before committing to an investment, the fund performs stringent due diligence and expects the highest standards from experienced management teams, realistic development plans, and a clear go-to-market strategy. Underpinned by clear value propositions, the fund is confident of achieving positive financial returns.

Since its inception, Helsinn Investment Fund has made investments in companies such as GreenBone, an Italian developer of bone regeneration technology, and Gain Therapeutics, a preclinical stage biotech company developing brain-penetrant non-competitive pharmacological chaperones for the treatment of devastating diseases. These investments reflect the fund's commitment to supporting innovative solutions in healthcare that address significant patient needs.